We hypothesized that a surplus of BACE1 would lead to increased Aβ34, given that BACE1 levels are significantly elevated in AD, while APP levels and Aβ40 and Aβ42 production rates do not change29. This evidence concerns the gene BACE1 and Alzheimer disease.